Rare Diseases Forum 1
Wednesday, October 17, 2018
Carnegie Endowment for International Peace
Participant List

Qais Abu Ali, MD
Medical Director
Ultragenyx Pharmaceutical

Nicholas Ah Mew, MD
Director, Inherited Metabolic Disorders Program
Children’s National

Stephen Aselage
Chief Executive Officer
Retrophin

Barry Byrne, MD, PhD
Director, Powell Center for Rare Disease Research & Therapy
University of Florida

Michelle Campbell, PhD
Reviewer and Scientific Coordinator
U.S. Food and Drug Administration

Abigail Barth
Associate Public Policy & Special Projects
Amicus Therapeutics

Annetta Beauregard, MBA, MS
Vice President, Regulatory Policy & Operations
Vertex Pharmaceuticals

Lisa Carlton, MS, PhD
Senior Director, Regulatory Affairs
REGENXBIO Inc.

Wen-Hung Chen, PhD
Lead Clinical Analyst
U.S. Food and Drug Administration

Jennifer Bernstein, MA
Executive Vice President
Horizon Government Affairs

Yeh-Fong Chen, PhD
Mathematical Statistician, Team Lead
U.S. Food and Drug Administration

Susan Berry, MD
Professor of Pediatrics
University of Minnesota

John F. Crowley, JD, MBA
Chairman and CEO
Amicus Therapeutics

Melanie Blank, MD
Medical Officer
U.S. Food and Drug Administration

Althea Cuff, MS
Science Policy Analyst
U.S. Food and Drug Administration

Tara Britt
Associate Chair
NC Rare Disease Advisory Council, UNC Medicine

Terry Daniels, MPH
Administrative Officer
Forum for Collaborative Research

P.J. Brooks, PhD
Program Director, Office of Rare Diseases Research
National Center for Advancing Translational Sciences, National Institutes of Health

Mark Dant
Chair, Board of Directors
EveryLife Foundation for Rare Diseases

* Denotes remote participation

Ebony Dashiell-Aje, PhD
Social Scientist, Clinical Outcome Assessments Reviewer
U.S. Food and Drug Administration
<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Davis, MA</td>
<td>Chief Executive Officer, Tavistock Group</td>
</tr>
<tr>
<td>Ellie Dehoney, MPH</td>
<td>Vice President, Policy and Advocacy Research!America</td>
</tr>
<tr>
<td>Jenny Doan, MSN, BSN*</td>
<td>Regulatory Project Manager, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Kathleen Donohue, MD</td>
<td>Lead Medical Officer, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Monique Fleck</td>
<td>Regulatory Affairs Manager, Amicus Therapeutics</td>
</tr>
<tr>
<td>Margie Frazier, PhD, MSW</td>
<td>Immediate Past Executive Director, Batten Disease Support and Research Association</td>
</tr>
<tr>
<td>Danielle Friend, PhD</td>
<td>Director, Science and Regulatory Affairs, Biotechnology Innovation Organization</td>
</tr>
<tr>
<td>Beth Frigola-McGinn</td>
<td>Co-Founder, Executive Director, A Cure for Ellie</td>
</tr>
<tr>
<td>Ilan Ganot, MBA</td>
<td>Founder, CEO, President, Solid Biosciences</td>
</tr>
<tr>
<td>Lili Garrard, PhD*</td>
<td>Mathematical Statistician, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Jayne Gershkowitz</td>
<td>Chief Patient Advocate, Amicus Therapeutics</td>
</tr>
<tr>
<td>Nancy Goodman, JD</td>
<td>Executive Director, Kids V Cancer</td>
</tr>
<tr>
<td>Katherine Greene, MPH</td>
<td>Senior Research Associate, Forum for Collaborative Research</td>
</tr>
<tr>
<td>Elizabeth Hart, MD</td>
<td>Medical Officer, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Luis Javier Hernandez</td>
<td>Project Manager, Forum for Collaborative Research</td>
</tr>
<tr>
<td>Christine Hon, PharmD</td>
<td>Pharmacologist, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Sophia Hufnagel, MD*</td>
<td>Medical Officer, Pediatric Geneticist, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Ilan Irony, MD</td>
<td>Deputy Division Director, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Dave Jacoby, MD, PhD</td>
<td>Fellow, VP, Head of Clinical Science, BioMarin Pharmaceutical</td>
</tr>
<tr>
<td>Dilara Jappar, PhD</td>
<td>Clinical Pharmacologist, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Linda Jeng, MD, PhD*</td>
<td>Medical Officer, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Julia Jenkins</td>
<td>Executive Director, EveryLife Foundation for Rare Diseases</td>
</tr>
<tr>
<td>Devanand Jillapalli, MD</td>
<td>Medical Officer, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Laura Lee Johnson, PhD</td>
<td>Director, Division Of Biometrics III, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Amel Karaa, MD</td>
<td>Assistant Professor &amp; Director, Harvard Medical School &amp; Massachusetts General Hospital</td>
</tr>
</tbody>
</table>

* Denotes remote participation
Rare Diseases Forum 1: Participant List

October 17, 2018

Sean Kassen, PhD
Director, Ara Parseghian Medical Research Fund
University of Notre Dame

Lucas Kempf, MD
Acting Associate Director, Rare Diseases Program
U.S. Food and Drug Administration

Vivian Kessler, RAC
Executive Director, Global Regulatory Affairs
Amicus Therapeutics

Sharon King, BA
President
North Carolina Rare Disease Coalition & Taylor’s Tale

Priya Kishnani, MD*
Professor of Pediatrics & Division Chief for Medical Genetics
Duke University Medical Center

Genevieve Laforet, MD, PhD
Senior Director, Clinical R&D
Solid Biosciences

Josh Lehrer, MD
Senior Vice President
Global Blood Therapeutics

Sandra Lehrman, MD
Independent Consultant & Patient Advocate

Harvey Levy, MD*
Senior Physician, Medicine/Genetics
Boston Children's Hospital & Harvard Medical School

Caroline Loewy
Co-Founder & Board Member
KCNQ2 Cure Alliance

Nicola Longo, MD, PhD*
Professor And Chief, Medical Genetics
University of Utah

Erica Lyons, MD
Medical Officer
U.S. Food and Drug Administration

Erin MacLeod, PhD, RD
Director, Metabolic Nutrition
Children's National Rare Disease Institute

Jeffrey Marrazzo, MPA, MBA
Chief Executive Officer
Spark Therapeutics

Scott McGooohan, JD
Director, US Regulatory Policy & Intelligence
Vertex Pharmaceuticals

Veronica Miller, PhD
Executive Director
Forum for Collaborative Research

Ken Mills, SB
President & CEO
REGENXBIO Inc.

Min Min, PhD*
Mathematical Statistician
U.S. Food and Drug Administration

Christine Mueller, DO
Medical Officer
U.S. Food and Drug Administration

Andrew Mulberg, MD
Vice President Global Regulatory Affairs
Amicus Therapeutics

Lily (Yeruk) Mulugeta, PharmD
Clinical Reviewer,
U.S. Food and Drug Administration

Adora Ndu, PharmD, JD
Executive Director, Regulatory Affairs
BioMarin Pharmaceutical

Mary Newman, MS
Senior Vice President, Regulatory Affairs
Audentes Therapeutics

Susan Nichols
Chief Executive Officer
Falcon Therapeutics

Bindi Nikhar, MD
Acting Deputy Division Director
U.S. Food and Drug Administration

* Denotes remote participation
Stephanie Omokaro, MD  
Lead Medical Officer  
U.S. Food and Drug Administration

Patroula Smpokou, MD  
Lead Medical Officer  
U.S. Food and Drug Administration

Nancy Parsons, MSc  
Vice President, Leadiant Biosciences

Donna Snyder, MD  
Senior Pediatric Ethicist  
U.S. Food and Drug Administration

Jackye Peretz, PhD  
Toxicologist  
U.S. Food and Drug Administration

Lisa Soule, MD  
Associate Director, DGIEP  
U.S. Food and Drug Administration

Forbes Porter, MD, PhD  
Senior Investigator And Clinical Director  
National Center for Advancing Translational Sciences, National Institutes of Health

Scott J. Steele, Ph.D.  
Director, Regulatory Science Programs  
Clinical and Translational Science Institute  
Associate Professor, University of Rochester

Mark Pykett, VMD, PhD*  
Chief Innovation Officer  
PTC Therapeutics

Kristin Stephenson, MHA, JD  
Sr. VP, Chief Policy & Community Engagement Officer  
Muscular Dystrophy Association

Jorge Quiroz, MD, MBA  
Chief Medical Officer  
Solid Biosciences

Marshall L. Summar, MD  
Chief of Genetics and Metabolism & Director, Rare Disease Institute  
Children’s National Medical Center

Brenda Rodriguez, MBA, MSc  
Development Manager  
Forum for Collaborative Research

Pranoot Tanpaiboon, MD  
Associate Medical Director, Advanced Diagnostics Genetics, Genomics and R&D, Biochemical Genetics, Quest Diagnostics

Dragos Roman, MD  
Medical Officer  
U.S. Food and Drug Administration

Cynthia Tifft, MD, PhD  
Director, Pediatric Undiagnosed Diseases Program, National Human Genome Research Institute, NIH

Frank Sasinowski, MS, MPH, JD  
Director  
Hyman, Phelps & McNamara, P.C.

Bruce Schneider, MD  
Medical Officer, Team Leader  
U.S. Food and Drug Administration

Bruce Turner, MD, PhD  
Managing Director  
Tavistock Group

Robert Schuck, PharmD, PhD  
Clinical Pharmacologist  
U.S. Food and Drug Administration

Julienne, Vaillancourt. RPh, MPH  
Rare Diseases Liaison  
U.S. Food and Drug Administration

Shirley Seo, PhD  
Division Director, Division of Clinical Pharmacology  
U.S. Food and Drug Administration

Tracy VanHoutan  
President  
Noah’s Hope Foundation - Batten Disease

Jeffrey Sherman, MD, FACP  
Chief Medical Officer and Executive Vice President  
Horizon Pharma, Inc

Jerry Vockley, MD, PhD  
Chief Medical Genetics  
University of Pittsburgh

* Denotes remote participation
Hong Vu, PharmD, MS, GWCPM
Regulatory Project Manager
U.S. Food and Drug Administration

Heidi L. Wagner, J.D.
SVP, Government Affairs & Policy
Global Blood Therapeutics

Jie (Jack) Wang, PhD
Lead Pharmacologist
U.S. Food and Drug Administration

Ron Wange, PhD
Associate Director for Pharmacology & Toxicology
U.S. Food and Drug Administration

Jessica Weber, BSN, MSc
Senior Research Associate
Forum for Collaborative Research

Holly Weng, MD, MHS
Executive Medical Director
BioMarin Pharmaceutical

David Whiteman, MD
Global Development Lead, Rare Metabolic Diseases, R&D
Shire Pharmaceuticals

Chester Whitley, PhD, MD
Professor, College of Pharmacy
University of Minnesota

David Williams, MBA
President
Health Business Group

Matt Wilsey, MBA
President & Chief Executive Officer
Grace Science Foundation

Rachel Witten, MD
Medical Officer
U.S. Food and Drug Administration

Janet Woodcock, MD
Director, Center for Drug Evaluation & Research
U.S. Food and Drug Administration

Dina Zand, MD
Medical Officer
U.S. Food and Drug Administration

* Denotes remote participation